Clinical Trials Browser

Phase 3 × Has announcements × Prostatic Neoplasms × Clear all

NCT01946204 2026-05-11

SPARTAN

Phase 3 Active not recruiting

1,207 enrolled 15 charts 1 FDA

Prostatic Neoplasms

NCT02489318 2026-05-11

TITAN

Phase 3 Active not recruiting

1,052 enrolled 13 charts 1 FDA

Prostatic Neoplasms

NCT02319837 2026-05-07

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Phase 3 Active not recruiting

1,068 enrolled 20 charts 1 FDA

Prostatic Neoplasms

NCT04689828 2026-03-23

PSMAfore

Phase 3 Active not recruiting

469 enrolled 11 charts 1 FDA

Prostatic Neoplasms

NCT02003924 2026-01-27

PROSPER

Phase 3 Completed

1,401 enrolled 25 charts 1 FDA

Prostatic Neoplasms

NCT01715285 2025-02-04

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

Phase 3 Completed

1,209 enrolled 16 charts 1 FDA

Prostatic Neoplasms

NCT03511664 2025-01-13

VISION

Phase 3 Completed

861 enrolled 39 charts 1 FDA

Prostatic Neoplasms

NCT03085095 2022-01-18

HERO

Phase 3 Completed

1,134 enrolled 38 charts 1 FDA

Prostatic Neoplasms